Hormone therapy is the most effective treatment for most menopausal symptoms, but it is not the only effective treatment — and it is not appropriate for every woman. Women with a history of hormone-sensitive breast cancer, recent cardiovascular events, active blood clots, or other contraindications to systemic estrogen require a management approach that achieves meaningful symptom relief without hormone use. Women who have effective options available but prefer to avoid hormones for personal reasons also deserve a comprehensive, evidence-based discussion of what non-hormonal management can achieve.
The non-hormonal treatment landscape for menopause has expanded meaningfully in recent years. The approval of fezolinetant (Veozah) in 2023 introduced the first specifically developed non-hormonal agent targeting the neurokinin B pathway that drives hot flashes — a mechanism distinct from the earlier repurposed options. A range of other prescription agents provides vasomotor relief through different mechanisms. Local non-hormonal options address genitourinary symptoms. And evidence-based behavioral approaches contribute meaningfully when integrated with pharmacologic treatment.
This page provides a clear, honest overview of what non-hormonal management can and cannot achieve — so that women who need or prefer this approach can make informed decisions about the options available to them.
The following prescription agents provide clinically meaningful reduction in hot flash frequency and severity without hormonal mechanisms. They are appropriate for women who are not candidates for hormone therapy or who prefer non-hormonal management.
Fezolinetant (Veozah) — The Newest and Most Specifically Targeted Option
Fezolinetant is a neurokinin 3 (NK3) receptor antagonist approved by the FDA in 2023 specifically for moderate to severe vasomotor symptoms of menopause. It targets the KNDy neurons in the hypothalamus that are the primary driver of vasomotor symptoms, reducing hot flash frequency and severity through a mechanism that is entirely distinct from hormonal approaches. Clinical trials demonstrated reduction in hot flash frequency of approximately 50 to 60 percent over placebo. Fezolinetant is taken daily and is generally well-tolerated. It is the most specifically developed non-hormonal option for vasomotor symptoms and represents a meaningful advance in this therapeutic area.
Paroxetine (Brisdelle) — The Only FDA-Approved SSRI for Vasomotor Symptoms
Paroxetine at low dose (7.5 mg, marketed as Brisdelle) is the only SSRI with FDA approval specifically for vasomotor symptoms of menopause. It reduces hot flash frequency by approximately 35 to 50 percent versus placebo. It also provides mood and anxiety benefit, making it particularly useful for women with concurrent perimenopausal mood symptoms alongside vasomotor complaints. Standard antidepressant doses of paroxetine also provide vasomotor benefit but with more side effect burden. Paroxetine should not be used by women taking tamoxifen for breast cancer because of drug interaction that reduces tamoxifen efficacy.
Venlafaxine (Effexor) — Off-Label but Well-Evidenced
Venlafaxine, an SNRI antidepressant, is one of the most commonly used non-hormonal agents for vasomotor symptoms despite not carrying FDA approval specifically for this indication. Its dual serotonin and norepinephrine reuptake inhibition provides vasomotor benefit alongside mood and anxiety effects. It is particularly useful for women with concurrent anxiety or depression alongside vasomotor symptoms, and it is the SNRI of choice for breast cancer patients on tamoxifen because it does not significantly inhibit the CYP2D6 enzyme that tamoxifen requires for activation.
Gabapentin — Particularly Effective for Nocturnal Symptoms
Gabapentin, originally developed as an anticonvulsant, reduces hot flash frequency and severity through central nervous system mechanisms distinct from serotonergic pathways. It is particularly effective for nocturnal hot flashes and night sweats — making it a useful option for women whose primary symptom burden is sleep disruption from night sweats rather than daytime vasomotor symptoms. Sedation is a common side effect that can be leveraged as a sleep benefit when gabapentin is dosed primarily at bedtime.
Oxybutynin — A Newer Non-Hormonal Vasomotor Option
Oxybutynin, an anticholinergic agent used for overactive bladder, has demonstrated vasomotor symptom benefit in clinical trials and is increasingly used off-label for hot flashes. It provides meaningful reduction in hot flash frequency and severity with a different side effect profile than serotonergic agents. Anticholinergic side effects — including dry mouth and constipation — are considerations, particularly in older women where anticholinergic burden accumulation is a clinical concern.
Clonidine — Modest Benefit, Primarily for Selected Patients
Clonidine, an alpha-2 agonist, provides modest hot flash reduction and is occasionally used in women who cannot tolerate other options. Its efficacy is less consistent than the agents above and its side effect profile — including hypotension, dry mouth, and sedation — limits its use. It may have a role for women with concurrent hypertension where a dual benefit is possible.
Non-hormonal options are genuinely effective but are generally less effective than hormone therapy for vasomotor symptoms. Understanding what each option realistically achieves helps guide the management decision:
- Hormone therapy reduces hot flashes by 80-90% for most candidates
- Fezolinetant reduces hot flashes by approximately 50-60% vs. placebo
- SSRIs/SNRIs reduce hot flashes by approximately 35-50% vs. placebo
- Non-hormonal options do not address bone density loss or genitourinary symptoms as effectively as estrogen
Lapeer: (810) 969-4670 · Rochester Hills: (248) 923-3522
Non-hormonal management of genitourinary symptoms, mood changes, and bone health requires different approaches than vasomotor management. The following covers the most clinically relevant non-hormonal options for these domains.
Genitourinary Symptoms — Ospemifene and Non-Estrogen Options
For vaginal dryness and painful intercourse, the non-hormonal prescription options include ospemifene (Osphena) — an oral selective estrogen receptor modulator that is approved for dyspareunia from GSM and has tissue-selective estrogen-like effects on vaginal tissue without systemic estrogen exposure. Prasterone (Intrarosa), a vaginal DHEA product, also addresses GSM without systemic estrogen. Over-the-counter vaginal moisturizers used regularly reduce vaginal pH and maintain moisture with no hormonal activity. These options provide meaningful improvement for genitourinary symptoms in women who cannot or prefer not to use local vaginal estrogen.
Bone Health — Non-Estrogen Pharmacologic Options
For women who cannot take hormone therapy for bone protection, bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) are the first-line pharmacologic agents for osteoporosis prevention and treatment. They reduce fracture risk significantly and are appropriate for women with osteoporosis or high-risk osteopenia. Denosumab, raloxifene, and in severe cases anabolic agents are additional options matched to specific clinical circumstances. The foundational non-pharmacologic approach — calcium, vitamin D, and weight-bearing exercise — is recommended for all postmenopausal women.
Behavioral Approaches — What the Evidence Supports
Cognitive-behavioral therapy for menopause (CBT-M) has demonstrated efficacy for both vasomotor symptoms and associated mood changes in clinical trials, with effect sizes that are meaningful when combined with other management approaches. Mindfulness-based stress reduction reduces hot flash-related distress. Weight loss in women with obesity reduces vasomotor symptom severity. Trigger reduction — avoiding caffeine, alcohol, spicy foods, and warm environments — provides adjunctive benefit. These behavioral approaches are most effective as complements to pharmacologic management rather than as sole interventions for moderate to severe symptoms.
Supplements — What the Evidence Shows
Botanical supplements including black cohosh, phytoestrogens (soy isoflavones, red clover), evening primrose oil, and others are widely used by menopausal women. The evidence for most of them is inconsistent — some studies show modest benefit, others show no effect beyond placebo. They are not regulated for safety or efficacy in the way prescription medications are. For women with mild symptoms who prefer a non-prescription approach, the available evidence on specific supplements is part of the counseling conversation. For women with moderate to severe symptoms, supplements are unlikely to provide sufficient relief and are not a substitute for evidence-based pharmacologic options.
Non-hormonal menopause management at Lapeer Women’s Health is led by Dr. Ramona D. Andrei, MD, PhD, FACOG — with individualized selection of the most appropriate agents based on symptom profile, health history, and contraindications.
Symptom Profile and Health History
The specific combination of symptoms driving the management need — hot flashes, sleep disruption, mood changes, vaginal dryness — along with the health history considerations that make hormone therapy unavailable or undesired, guides the selection of non-hormonal agents. Different symptom profiles point toward different first-line options.
First-Line Agent Selection and Titration
Dr. Andrei selects the most appropriate first-line non-hormonal agent based on the clinical picture, discusses what to expect in terms of benefit and side effects, and establishes a follow-up timeline to assess response and adjust if needed. No treatment recommendation is made without a clear explanation of what the option can realistically achieve.
Comprehensive Coverage of the Full Symptom Burden
Non-hormonal management at Lapeer Women’s Health addresses the full symptom burden — not just vasomotor symptoms in isolation. Genitourinary symptoms, mood changes, sleep disruption, and bone health considerations are each addressed as part of a comprehensive plan rather than as an afterthought to the primary vasomotor management.
For women who have been told they cannot use hormone therapy — because of breast cancer history, cardiovascular concerns, or other contraindications — the expanded non-hormonal treatment landscape of 2026 looks meaningfully different than it did even five years ago. The approval of fezolinetant specifically for vasomotor symptoms, combined with the established options from SSRIs, SNRIs, and gabapentin, means that most women can achieve meaningful symptom reduction without hormones.
The right combination of non-hormonal agents for your specific symptom profile, health history, and preferences is the product of an individualized clinical discussion — not a generic handout. Dr. Ramona D. Andrei and the team at Lapeer Women’s Health are here for that discussion — at both our Lapeer and Rochester Hills offices, without a referral required.
Nonhormonal Menopause Options
Our team at Lapeer Women’s Health provides individualized non-hormonal menopause management at both our Lapeer and Rochester Hills offices — with a full discussion of what the evidence shows for each option. No referral required.
Schedule a Gynecologic VisitThe information on this page is intended for educational purposes only and does not constitute medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.